Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Garner

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Nature Methods|November 9, 2023
Author Correction: Mapping the genomic landscape of CRISPR-Cas9 cleavagePeter Cameron, Chris K Fuller, Paul D Donohoue, et al.
Cytotherapy|April 22, 2023
Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitnessElaine Lau, George Kwong, Tristan W Fowler, et al.
Cancer Immunology Research|February 12, 2024
High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical ModelsÉmilie Degagné, Paul D Donohoue, Suparna Roy, et al.
Journal of the National Cancer Institute|December 5, 2013
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trialWilliam Greenhalf, Paula Ghaneh, John P Neoptolemos, et al.
Cell|August 7, 2012
Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signalingMoumita Chaki, Rannar Airik, Amiya K Ghosh, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Nature Methods|November 9, 2023
Author Correction: Mapping the genomic landscape of CRISPR-Cas9 cleavagePeter Cameron, Chris K Fuller, Paul D Donohoue, et al.
Cytotherapy|April 22, 2023
Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitnessElaine Lau, George Kwong, Tristan W Fowler, et al.
Cancer Immunology Research|February 12, 2024
High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical ModelsÉmilie Degagné, Paul D Donohoue, Suparna Roy, et al.
Journal of the National Cancer Institute|December 5, 2013
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trialWilliam Greenhalf, Paula Ghaneh, John P Neoptolemos, et al.
Cell|August 7, 2012
Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signalingMoumita Chaki, Rannar Airik, Amiya K Ghosh, et al.
Pageof 3